How AstraZeneca Is Advancing Its Oncology Portfolio in 2019

How AstraZeneca Is Advancing Its Oncology Portfolio in 2019

On March 28, AstraZeneca (AZN) issued a press release announcing its collaboration with Daiichi Sankyo for the development and commercialization of trastuzumab deruxtecan, an investigational therapy currently being evaluated for multiple HER2-expressing cancers.